Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics

References

• Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–968.
   PubMed Web of Science ®Google Scholar
• Takebe T, Imai R, Ono S. The current status of drug discovery and development as originated in United States academia: the influence of industrial and academic collaboration on drug discovery and development. Clin Transl Sci. 2018;11:597–606.
   PubMed Web of Science ®Google Scholar
• Hughes B. FDA drug approvals. Nat Rev Drug Discov. 2009;8:93–96.
   PubMed Web of Science ®Google Scholar
• Hughes B. FDA drug approvals. Nat Rev Drug Discov. 2010;9:89–92.
   PubMed Web of Science ®Google Scholar
• Mullard A. FDA drug approvals. Nat Rev Drug Discov. 2019;18:85–89.
   PubMed Web of Science ®Google Scholar
• Amur S, LaVange L, Zineh I, et al. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther. 2015;98:34–46.
   PubMed Web of Science ®Google Scholar
• Sams-Dodd F. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift. Drug Discov Today. 2013;18:211–217.
   PubMed Web of Science ®Google Scholar
• Kell DB, Goodacre R. Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discov Today. 2014;19:171–182.
   PubMed Web of Science ®Google Scholar
• Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13:263–269.
   PubMed Web of Science ®Google Scholar
• Kumar B, Prakash A, Ruhela RK, et al. Potential of metabolomics in preclinical and clinical drug development. Pharmacol Rep. 2014;66:956–963.
   PubMed Web of Science ®Google Scholar
• Tolstikov V. Metabolomics: bridging the gap between pharmaceutical development and population health. Metabolites. 2016;6(3):E20.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Lindon JC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29:1181–1189.
   PubMed Web of Science ®Google Scholar
• Fiehn O. Metabolomics - the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–171.
   PubMed Web of Science ®Google Scholar
• Oliver SG, Winson MK, Kell DB, et al. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16:373–378.
   PubMed Web of Science ®Google Scholar
• Baker M. Metabolomics: from small molecules to big ideas. Nat Methods. 2011;2:219–221.
   Google Scholar
• Goodacre R. Metabolomics of a superorganism. J Nutr. 2007;137(1Suppl):259S–266S.
   PubMedGoogle Scholar
• Cuperlovic-Culf M, Culf AS. Applied metabolomics in drug discovery. Expert Opin Drug Discov. 2016;11(8):759–770.
   PubMed Web of Science ®Google Scholar
• Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451–459.
   PubMed Web of Science ®Google Scholar
• Gertsman I, Barshop BA. Promises and pitfalls of untargeted metabolomics. J Inherit Metab Dis. 2018;41:355–366.
   PubMed Web of Science ®Google Scholar
• Ren JL, Zhang AH, Kong L, et al. Advances in mass spectrometry-based metabolomics for investigation of metabolites. RSC Adv. 2018;8:22335.
   PubMed Web of Science ®Google Scholar
• Kirwan JA, Brennan L, Broadhurst D, et al. Preanalytical processing and biobanking procedures of biological samples for metabolomics research: a white paper, community perspective (for “precision medicine and pharmacometabolomics task group”-the metabolomics society initiative). Clin Chem. 2018;64:1158–1182.
   PubMed Web of Science ®Google Scholar
• Dubbelman AC, Cuyckens F, Dillen L, et al. Mass spectrometric recommendations for quan/qual analysis using liquid-chromatography coupled to quadrupole time-of-flight mass spectrometry. Anal Chim Acta. 2018;1020:62–75.
   PubMed Web of Science ®Google Scholar
• Emwas AH, Roy R, McKay RT, et al. Recommendations and standardization of biomarker quantification using nmr-based metabolomics with particular focus on urinary analysis. J Proteome Res. 2016;15:360–373.
   PubMed Web of Science ®Google Scholar
• Saurina J, Sentellas S. Liquid chromatography coupled to mass spectrometry for metabolite profiling in the field of drug discovery. Expert Opin Drug Discov. 2019;14(5):469–483.
   PubMed Web of Science ®Google Scholar
• Palmas F, Mussap M, Fattuoni C. Urine metabolome analysis by gas chromatography-mass spectrometry (GC-MS): standardization and optimization of protocols for urea removal and short-term sample storage. Clin Chim Acta. 2018;485:236–242.
   PubMed Web of Science ®Google Scholar
• González-Domínguez R, Sayago A, Fernández-Recamales Á. Direct infusion mass spectrometry for metabolomic phenotyping of diseases. Bioanalysis. 2017;9:131–148.
   PubMed Web of Science ®Google Scholar
• Markley JL, Brüschweiler R, Edison AS, et al. The future of NMR-based metabolomics. Curr Opin Biotechnol. 2017;43:34–40.
   PubMed Web of Science ®Google Scholar
• Dona AC, Kyriakides M, Scott F, et al. A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. Comput Struct Biotechnol J. 2016;14:135–153.
   PubMed Web of Science ®Google Scholar
• Ruiqi J, Jiao Y, Xu F. Chemical derivatization-based LC–MS for metabolomics: advantages and challenges. Bioanalysis. 2016;8(18):1881–1883.
   PubMed Web of Science ®Google Scholar
• Loss P, van de Waterbeemd M, Heck A. The diverse and expanding role of mass spectrometry in structural and molecular biology. Eur Mol Biol Org J. 2016;35:2634–2657.
   PubMed Web of Science ®Google Scholar
• Jiang H, Zeng J, Zheng N, et al. A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography/tandem mass spectrometry assay for plasma samples. Anal Chem. 2011;83:6237–6244.
   PubMed Web of Science ®Google Scholar
• Pacholski ML, Winograd N. Imaging with mass spectrometry. Chem Rev. 1999;99:2977.
   PubMed Web of Science ®Google Scholar
• Liebl H. Ion microprobe mass analyzer. J Appl Phys. 1967;38:5277.
   Web of Science ®Google Scholar
• Morrison GH, Slodzian G. Ion microscopy. Anal Chem. 1975;47:932–943.
   Web of Science ®Google Scholar
• Gamble LJ, Anderton CR. Secondary ion mass spectrometry imaging of tissues, cells, and microbial systems. Micros Today. 2016;24:24–31.
   PubMedGoogle Scholar
• Wiseman JM, Ifa DR, Zhu Y, et al. Desorption electrospray ionization mass spectrometry: imaging drugs and metabolites in tissues. Proc Natl Acad Sci U S A. 2008;105:18120–18125.
   PubMed Web of Science ®Google Scholar
• Cornett DS, Reyzer ML, Chaurand P, et al. MALDI imaging mass spectrometry: molecular snapshots of biochemical systems. Nat Methods. 2007;4:828–833.
   PubMed Web of Science ®Google Scholar
• Soltwisch J, Kettling H, Vens-Cappell S, et al. Mass spectrometry imaging with laser-induced postionization. Science. 2015;348(6231):211–215.
   PubMed Web of Science ®Google Scholar
• Nemes P, Vertes A. Laser ablation electrospray ionization for atmospheric pressure, in vivo, and imaging mass spectrometry. Anal. Chem. 2007;79:8098–8106.
   PubMed Web of Science ®Google Scholar
• Waki M, Sugiyama E, Kondo T, et al. Nanoparticle-assisted laser desorption/ionization for metabolite imaging. Methods Mol Biol. 2015;1203:159–173.
   PubMedGoogle Scholar
• Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997;69:4751–4760.
   PubMed Web of Science ®Google Scholar
• Seeley EH, Schwamborn K, Caprioli RM. Imaging of intact tissue sections: moving beyond the microscope. J Biol Chem. 2011;286:25459–25466.
   PubMed Web of Science ®Google Scholar
• Wiseman JM, Ifa DR, Zhu Y, et al. Desorption electrospray ionization mass spectrometry: imaging drugs and metabolites in tissues. Proc Natl Acad Sci U S A. 2008;105:18120–18125.
   PubMed Web of Science ®Google Scholar
• Swales JG, Hamma G, Clench MR, et al. Mass spectrometry imaging and its application in pharmaceutical research and development: a concise review. Int J Mass Spectrom. 2019;437:99–112.
   Web of Science ®Google Scholar
• Nishidate M, Hayashi M, Aikawa H, et al. Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metab Pharmacokinet. 2019;34:209–216.
   PubMed Web of Science ®Google Scholar
• Yang B, Tsui T, Caprioli RM, et al. Sample preparation and analysis of single cells using high performance MALDI FTICR mass spectrometry. Methods Mol Biol. 2020;2064:125–134.
   PubMedGoogle Scholar
• McDonnell LA, Angel PM, Lou S, et al. Mass spectrometry imaging in cancer research: future perspectives. Adv Cancer Res. 2017;134:283–290.
   PubMed Web of Science ®Google Scholar
• Vaysse P-M, Heeren RMARMA, Porta T, et al. Mass spectrometry imaging for clinical research - latest developments, applications, and current limitations. Analyst. 2017;142:2690–2712.
   PubMed Web of Science ®Google Scholar
• Chen K, Baluya D, Tosun M, et al. Imaging mass spectrometry: a new tool to assess molecular underpinnings of neurodegeneration. Metabolites. 2019;9:E135.
   PubMed Web of Science ®Google Scholar
• Dueñas ME, Larson EA, Lee YJ. Toward mass spectrometry imaging in the metabolomics scale: increasing metabolic coverage through multiple on-tissue chemical modifications. Front Plant Sci. 2019;10:860.
   PubMed Web of Science ®Google Scholar
• Xue J, Liu H, Chen S, et al. Mass spectrometry imaging of the in situ drug release from nanocarriers. Sci Adv. 2018;4:eaat9039.
   PubMed Web of Science ®Google Scholar
• Yin R, Burnum-Johnson KE, Sun X, et al. High spatial resolution imaging of biological tissues using nanospray desorption electrospray ionization mass spectrometry. Nat Protoc. 2019 Nov 13;14:3445–3470.
   PubMed Web of Science ®Google Scholar
• Vos DRN, Jansen I, Lucas M, et al. Strategies for managing multi-patient 3D mass spectrometry imaging data. J Proteomics. 2019;193:184–191.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429:464–468.
   PubMed Web of Science ®Google Scholar
• Roden DM, McLeod HL, Relling MV, et al. Pharmacogenomics. Lancet. 2019;394(10197):521–532.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Connelly J, Lindon JC, et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discovery. 2002;1:153–161.
   PubMed Web of Science ®Google Scholar
• Clayton TA, Lindon JC, Cloarec O, et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature. 2006;440:1073–1077.
   PubMed Web of Science ®Google Scholar
• Wilson ID. Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci USA. 2009;106:14187–14188.
   PubMed Web of Science ®Google Scholar
• Pang H, Jia W, Hu Z. Emerging applications of metabolomics in clinical pharmacology. Clin Pharmacol Ther. 2019;106:544–556.
   PubMed Web of Science ®Google Scholar
• Burt T, Nandal S. Pharmacometabolomics in early-phase clinical development. Clin Transl Sci. 2016;9:128–138.
   PubMed Web of Science ®Google Scholar
• Kantae V, Krekels EHJ, Esdonk MJV, et al. Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics. 2017;13:9.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics research network. pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther. 2014;95:154–167.
   PubMed Web of Science ®Google Scholar
• Balashova EE, Maslov DL, Lokhov PG. A metabolomics approach to pharmacotherapy personalization. J Pers Med. 2018;8(3):E28.
   PubMed Web of Science ®Google Scholar
• Fanos V, Van den Anker J, Noto A, et al. Metabolomics in neonatology: fact or fiction? Semin Fetal Neonatal Med. 2013;18:3–12.
   PubMed Web of Science ®Google Scholar
• Powers R. The current state of drug discovery and a potential role for NMR metabolomics. J Med Chem. 2014;57(14):5860–5870.
   PubMed Web of Science ®Google Scholar
• Baraldi E, Carraro S, Giordano G, et al. Metabolomics: moving towards personalized medicine. Ital J Ped. 2009;35:30. Kroemer HK, Meyer zu Schwabedissen HE. A piece in the puzzle of personalized medicine. Clin Pharmacol Ther. 2010;87:19-20.
   PubMed Web of Science ®Google Scholar
• Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009;106(34):14728–14733.
   PubMed Web of Science ®Google Scholar
• Katsila T, Patrinos GP. Pharmacometabolomics: applications and challenges. Curr Pharmacogenomics Person Med. 2015;13:9–13.
   Google Scholar
• Abo R, Hebbring S, Ji Y, et al. Merging pharmacometabolomics with pharmacogenomics using ‘1000 genomes’ single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics. 2012;22:247–253.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Everett JR, Lindon JC. Longitudinal pharmacometabonomics for predicting patient responses to therapy: drug metabolism, toxicity and efficacy. Expert Opin Drug Metab Toxicol. 2012;8:135–139.
   PubMed Web of Science ®Google Scholar
• Katsila T, Balasopoulou A, Tsagaraki I, et al. Pharmacomicrobiomics informs clinical pharmacogenomics. Pharmacogenomics. 2019;20:731–739.
   PubMed Web of Science ®Google Scholar
• Wishart DS. Application of metabolomics in drug discovery and development. Drugs R D. 2008;9(5):307–322.
   PubMed Web of Science ®Google Scholar
• Everett JR. From metabonomics to pharmacometabonomics: the role of metabolic profiling in personalized medicine. Front Pharmacol. 2016;7:297.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.
   PubMed Web of Science ®Google Scholar
• Sugiura Y, Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol. 2010;5:31–43.
   PubMed Web of Science ®Google Scholar
• Végvári Á. Drug localizations in tissue by mass spectrometry imaging. Biomark Med. 2015;9:869–876.
   PubMed Web of Science ®Google Scholar
• Jove M, Spencer J, Clench M, et al. Precision pharmacology: mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol. 2019;141:153–162.
   PubMed Web of Science ®Google Scholar
• Johnson RW Jr, Talaty N. Tissue imaging by mass spectrometry: a practical guide for the medicinal chemist. ACS Med Chem Lett. 2019;10:161–167.
   PubMed Web of Science ®Google Scholar
• Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–485.
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66:1154–1164.
   PubMed Web of Science ®Google Scholar
• García-Cañaveras JC, Castell JV, Donato MT, et al. A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. Sci Rep. 2016;6:27239.
   PubMed Web of Science ®Google Scholar
• Mazaleuskaya LL, Sangkuhl K, Thorn CF, et al. PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015;25:416–426.
   PubMed Web of Science ®Google Scholar
• Chen C, Krausz KW, Shah MY, et al. Serum metabolomics reveals irreversible inhibition of fatty acid-oxidation through the suppression of pparr activation as a contributing mechanism of acetaminophen-induced hepatotoxicity. Chem Res Toxicol. 2009;22:699–707.
   PubMed Web of Science ®Google Scholar
• Andersson U, Lindberg J, Wang S, et al. A systems biology approach to understanding elevated serum alanine transaminase levels in a clinical trial with ximelagatran. Biomarkers. 2009;14:572–586.
   PubMed Web of Science ®Google Scholar
• Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;196:407–418.
   PubMedGoogle Scholar
• Mattes WB. Public consortium efforts in toxicogenomics. Methods Mol Biol. 2008;460:221–238.
   PubMedGoogle Scholar
• Ellinger-Ziegelbauer H, Adler M, Amberg A, et al. The enhanced value of combining conventional and “omics” analyses in early assessment of drug-induced hepatobiliary injury. Toxicol Appl Pharmacol. 2011;252:97–111.
   PubMed Web of Science ®Google Scholar
• Chang H, Meng HY, Liu SM, et al. Identification of key metabolic changes during liver fibrosis progression in rats using a urine and serum metabolomics approach. Sci Rep. 2017;7:11433.
   PubMed Web of Science ®Google Scholar
• O’Connell TM, Watkins PB. The application of Metabolomics to predict drug-induced liver injury. Clin Pharmacol Ther. 2010;88:394–399.
   PubMed Web of Science ®Google Scholar
• Fanos V, Barberini L, Antonucci R, et al. Pharma-metabolomics in neonatology: is it a dream or a fact? Curr Pharm Des. 2012;18:2996–3006.
   PubMed Web of Science ®Google Scholar
• Ghosh SP, Singh R, Chakraborty K, et al. Metabolomic changes in gastrointestinal tissues after whole body radiation in a murine model. Mol Biosyst. 2013;9:723–731.
   PubMed Web of Science ®Google Scholar
• Um SY, Chung MW, Kim KB, et al. Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats. Anal Chem. 2009;81:4734–4741.
   PubMed Web of Science ®Google Scholar
• Forsgård RA, Marrachelli VG, Korpela K, et al. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male sprague-dawley rats. Cancer Chemother Pharmacol. 2017;80:317–332.
   PubMed Web of Science ®Google Scholar
• IPCS CEC (International Programme on Chemical Safety, Commission of the European Communities). Principle and methods for the assessment of nephrotoxicity associated with exposure to chemicals. Environmental Health Criteria 119. Geneva: WHO, 1991
   Google Scholar
• Mussap M, Noto A, Fanos V, et al. Emerging biomarkers and metabolomics for assessing toxic nephropathy and acute kidney injury (AKI) in neonatology. Biomed Res Int. 2014;2014:602526.
   PubMed Web of Science ®Google Scholar
• Williams RE, Major H, Lock EA, et al. D-Serine-induced nephrotoxicity: a HPLC-TOF/MS-based metabonomics ap- proach. Toxicology. 2005;207:179–190.
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Knight R, et al. Metabonomics with 1H- NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers. 2005;10:173–187.
   PubMed Web of Science ®Google Scholar
• Lenz EM, Bright J, Knight R, et al. A metabonomic investigation of the biochemical effects of mercuric chloride in the rat using 1H NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst. 2004;129:535–541.
   PubMed Web of Science ®Google Scholar
• Lindon JC, Holmes E, Bollard ME, et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9:1–3.
   PubMed Web of Science ®Google Scholar
• Boudonck KJ, Matthew W, Mitchell MW, et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol. 2009;37:280–292.
   PubMed Web of Science ®Google Scholar
• Lv H, Liu L, Zhang Y, et al. Ingenuity pathways analysis of urine metabonomics phenotypes toxicity of gentamicin in multiple organs. Mol Biosyst. 2010;6:2056–2067.
   PubMedGoogle Scholar
• Espandiari P, Zhang J, Rosenzweig BA, et al. The utility of a rodent model in detecting pediatric drug-induced nephrotoxicity. Toxicol Sci. 2007;99:637–648.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Haschke M, Kahle C, et al. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol. 2010;70:241–251.
   PubMed Web of Science ®Google Scholar
• Klawitter J, Klawitter J, Kushner E, et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res. 2010;9:865–875.
   PubMed Web of Science ®Google Scholar
• Zhang P, Li W, Chen J, et al. Branched-chain amino acids as predictors for individual differences of cisplatin nephrotoxicity in rats: a pharmacometabonomics study. J Proteome Res. 2017;16:1753–1762.
   PubMed Web of Science ®Google Scholar
• Ryu SH, Lee JD, Kim JW, et al. 1H NMR toxicometabolomics following cisplatin-induced nephrotoxicity in male rats. J Toxicol Sci. 2019;44:57–71.
   PubMed Web of Science ®Google Scholar
• Sethi S, Brietzke E. Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2016;19:1–13.
   Web of Science ®Google Scholar
• Lanznaster D, de Assis DR, Corcia P, et al. Metabolomics biomarkers: a strategy toward therapeutics improvement in ALS. Front Neurol. 2018;9:1126.
   PubMed Web of Science ®Google Scholar
• Walker DI, Perry-Walker K, Finnell RH, et al. Metabolome-wide association study of anti-epileptic drug treatment during pregnancy. Toxicol Appl Pharmacol. 2019;363:122–130.
   PubMed Web of Science ®Google Scholar
• Wood AG, Nadebaum C, Anderson V, et al. Prospective assessment of autism traits in children exposed to antiepileptic drugs during pregnancy. Epilepsia. 2015;56:1047–1055.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, Hankemeier T, Scholl, et al. Pharmacometabolomics informs about pharmacokinetic profile of methylphenidate. CPT Pharmacometrics Syst Pharmacol. 2018;7:525–533.
   PubMedGoogle Scholar
• Gupta M, Neavin D, Liu D, et al. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Mol Psychiatry. 2016;21(12):1717–1725.
   PubMed Web of Science ®Google Scholar
• Rotroff DM, Corum DG, Motsinger-Reif A, et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Transl Psychiatry. 2016;6:e894.
   PubMed Web of Science ®Google Scholar
• Lan MJ, McLoughlin GA, Griffin JL, et al. Metabonomic analysis identifies molecular changes associated with the pathophysiology and drug treatment of bipolar disorder. Mol Psichiatry. 2009;14:269–279.
   PubMed Web of Science ®Google Scholar
• Kaddurah-Daouk R, McEvoy J, Baillie RA, et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry. 2007;12:934–945.
   PubMed Web of Science ®Google Scholar
• van den Brink WJ, Elassaiss-Schaap J, Gonzalez-Amoros B, et al. Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats. Eur J Pharm Sci. 2017;109:431–440.
   PubMed Web of Science ®Google Scholar
• Sreekumar A, Poisson LM, Rajendiran TM, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910–914.
   PubMed Web of Science ®Google Scholar
• Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19:17–30.
   PubMed Web of Science ®Google Scholar
• Tiziani S, Lodi A, Khanim FL, et al. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. Plos One. 2009;4:e4251.
   PubMed Web of Science ®Google Scholar
• Bayet-Robert M, Morvan D, Chollet P, et al. Pharmacometabolomics of docetaxel-treated human MCF7 breast cancer cells provides evidence of varying cellular responses at high and low doses. Breast Cancer Res Treat. 2010;120:613–626.
   PubMed Web of Science ®Google Scholar
• de Man FM, Goey AK, van Schaik RH, et al. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet. 2018;57(10):1229-1254.
   PubMedGoogle Scholar
• Gao Y, Li W, Chen J, et al. Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats. Acta Pharm Sin B. 2019;9:157–166.
   PubMed Web of Science ®Google Scholar
• Bao X, Wu J, Kim S, et al. Pharmacometabolomics reveals irinotecan mechanism of action in cancer patients. J Clin Pharmacol. 2019;59:20–34.
   PubMed Web of Science ®Google Scholar
• Miolo G, Muraro E, Caruso D, et al. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget. 2016;7:39809–39822.
   PubMedGoogle Scholar
• Speck RM, Sammel MD, Farrar JT, et al. Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract. 2013;9:e234–e240.
   PubMedGoogle Scholar
• Sun Y, Kim JH, Vangipuram K, et al. Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat. 2018;171:657–666.
   PubMed Web of Science ®Google Scholar
• Min KW, Bang JY, Kim KP, et al. Imaging mass spectrometry in papillary thyroid carcinoma for the identification and validation of biomarker proteins. J Korean Med Sci. 2014;29:934–940.
   PubMed Web of Science ®Google Scholar
• Gardner-Thorpe J, Ito H, Ashley SW, et al. Ribosomal protein P2: a potential molecular target for antisense therapy of human malignancies. Anticancer Res. 2003;23:4549–4560.
   PubMed Web of Science ®Google Scholar
• Paine MRL, Liu J, Huang D, et al. Three-dimensional mass spectrometry imaging identifies lipid markers of medulloblastoma metastasis. Sci Rep. 2019;9:2205.
   PubMed Web of Science ®Google Scholar
• Morse N, Jamaspishvili T, Simon D, et al. Reliable identification of prostate cancer using mass spectrometry metabolomic imaging in needle core biopsies. Lab Invest. 2019;99:1561–1571.
   PubMed Web of Science ®Google Scholar
• N B, K R C. Tetrandrine and cancer – an overview on the molecular approach. Biomed Pharmacother. 2018;97:624–632.
   PubMed Web of Science ®Google Scholar
• Tang W, Chen J, Zhou J, et al. Quantitative MALDI imaging of spatial distributions and dynamic changes of tetrandrine in multiple organs of rats. Theranostics. 2019;9:932–944.
   PubMed Web of Science ®Google Scholar
• Ghanbari R, Sumner S. Using metabolomics to investigate biomarkers of drug addiction. Trends Mol Med. 2018;24:197–205.
   PubMed Web of Science ®Google Scholar
• Deng Y, Bu Q, Hu Z, et al. (1)H-nuclear magnetic resonance- based metabonomic analysis of brain in rhesus monkeys with morphine treatment and withdrawal intervention. J Neurosci Res. 2012;90:2154–2162.
   PubMed Web of Science ®Google Scholar
• Li H, Chen B, Shao X, et al. 1H-Nuclear magnetic resonance-based metabolomic analysis of brain in mice with nicotine treatment. BMC Neurosci. 2014;15:32.
   PubMed Web of Science ®Google Scholar
• Zheng T, Liu L, Aa J, et al. Metabolic phenotype of rats exposed to heroin and potential markers of heroin abuse. Drug Alcohol Depend. 2013;127:177–186.
   PubMed Web of Science ®Google Scholar
• Zheng T, Liu L, Shi J, et al. The metabolic impact of methamphetamine on the systemic metabolism of rats and potential markers of methamphetamine abuse. Mol Biosyst. 2014;10:1968–1977.
   PubMed Web of Science ®Google Scholar
• Ning T, Leng C, Chen L, et al. Metabolomics analysis of serum in a rat heroin self-administration model undergoing reinforcement based on 1 H-nuclear magnetic resonance spectra. BMC Neurosci. 2018;19:4.
   PubMed Web of Science ®Google Scholar
• Meinhardt MW, Sévin DC, Klee ML, et al. The neurometabolic fingerprint of excessive alcohol drinking. Neuropsychopharmacol. 2015;40:1259–1268.
   PubMed Web of Science ®Google Scholar
• Würtz P, Cook S, Wang Q, et al. Metabolic profiling of alcohol consumption in 9778 young adults. Int J Epidemiol. 2016;45:1493–1506.
   PubMed Web of Science ®Google Scholar
• Yang Z, Kusumanchi P, Ross RA, et al. Serum metabolomic profiling identifies key metabolic signatures associated with pathogenesis of alcoholic liver disease in humans. Hepatol Commun. 2019;3:542–557.
   PubMed Web of Science ®Google Scholar
• Ghanbari R, Sumner S. Using metabolomics to investigate biomarkers of drug addiction. Trends Mol Med. 2018;24:197–205.
   PubMed Web of Science ®Google Scholar
• Genschow E, Spielmann H, Scholz G, et al. The ECVAM international validation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European centre for the validation of alternative methods. Altern Lab Anim. 2002;30:151–176.
   PubMed Web of Science ®Google Scholar
• Cezar GG, Quam JA, Smith AM, et al. Identification of small molecules from human embryonic stem cells using metabolomics. Stem Cells Dev. 2007;16:869–882.
   PubMed Web of Science ®Google Scholar
• West PR, Weir AM, Smith AM, et al. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol. 2010;247:18–27.
   PubMed Web of Science ®Google Scholar
• Kleinstreuer NC, Smith AM, West PR, et al. Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol. 2011;257:111–121.
   PubMed Web of Science ®Google Scholar
• Götherström C. Human foetal mesenchymal stem cells. Best Pract Res Clin Obstet Gynaecol. 2016;31:82–87.
   PubMed Web of Science ®Google Scholar
• Moroni L, Fornasari PM. Human mesenchymal stem cells: a bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues. Cell Physiol. 2013;228:680–687.
   Google Scholar
• Klontzas ME, Vernardis SI, Heliotis M, et al. Metabolomics analysis of the osteogenic differentiation of umbilical cord blood mesenchymal stem cells reveals differential sensitivity to osteogenic agents. Stem Cells Dev. 2017;26:723–733.
   PubMed Web of Science ®Google Scholar
• Fanos V, Antonucci R, Barberini L, et al. Clinical application of metabolomics in neonatology. J Matern Fetal Neonatal Med. 2012;25(S1):104–109.
   PubMedGoogle Scholar
• Mussap M, Antonucci R, Noto A, et al. The role of metabolomics in neonatal and pediatric laboratory medicine. Clin Chim Acta. 2013;426:127–138.
   PubMed Web of Science ®Google Scholar
• van den Anker J, Reed MD, Allegaert K, et al. Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2018;58(Suppl 10):S10–S25.
   PubMed Web of Science ®Google Scholar
• Gow PJ, Ghabrial H, Smallwood RA, et al. Neonatal hepatic drug elimination. Toxicol Pharmacol. 2001;88:3–15.
   PubMedGoogle Scholar
• Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(Suppl 3):53–59.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–1167.
   PubMed Web of Science ®Google Scholar
• Cook SF, Stockmann C, Samiee-Zafarghandy S, et al. Neonatal maturation of paracetamol (acetaminophen) glucuronidation, sulfation, and oxidation based on a parent-metabolite population pharmacokinetic model. Clin Pharmacokinet. 2016;55:1395–1411.
   PubMed Web of Science ®Google Scholar
• Pacifici GM. Metabolism and pharmacokinetics of morphine in neonates: A review. Clinics (Sao Paulo). 2016;71:474–480.
   PubMed Web of Science ®Google Scholar
• Lewis T, Chalise P, Gauldin C, et al. Pharmacometabolomics of respiratory phenotypic response to dexamethasone in preterm infants at risk for bronchopulmonary dysplasia. Clin Transl Sci. 2019;12:591–599.
   PubMedGoogle Scholar
• Fabiano A, Gazzolo D, Zimmermann LJ, et al. Metabolomic analysis of bronchoalveolar lavage fluid in preterm infants complicated by respiratory distress syndrome: preliminary results. J Matern Fetal Neonatal Med. 2011;24(Suppl 2):55–58.
   PubMed Web of Science ®Google Scholar
• Dedja A, Gucciardi A, Giordano G, et al. Lipopolysaccharide-induced chorioamnionitis and postnatal lung injury: the beneficial effects of L-citrulline in newborn rats. Exp Lung Res. 2018;44:226–240.
   PubMed Web of Science ®Google Scholar
• Atzori L, Barberini L, Lussu M, et al. Metabolomics & patent ductus arteriosus diagnosis: is 1H-NMR (nuclear magnetic resonace) spectroscopy of urine at birth predictive as ultrasound? J Matern Fetal Neonatal Med. 2012;25:Issue sup5.
   Google Scholar
• Liu Z, Liu R, Chou J, et al. Targeted metabolomics analysis reveals the association between maternal folic acid supplementation and fatty acids and amino acids profiles in rat pups. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1090:101–109.
   PubMed Web of Science ®Google Scholar
• Cesare Marincola F, Dessì A, Corbu S, et al. Clinical impact of human breast milk metabolomics. Clin Chim Acta. 2015;451(Pt A):103–106.
   PubMedGoogle Scholar
• Escherich T. Die Darmbakterien des Säuglings. Stuttgart, Germany: ArbA D Path InstzuMünchen; 1886; p. 1–180.
   Google Scholar
• Dogra S, Sakwinska O, Soh SE, et al. Dynamics of infant gut microbiota are influenced by delivery mode and gestational duration and are associated with subsequent adiposity. mBio. 2015;6:e02419.
   PubMed Web of Science ®Google Scholar
• Rodríguez JM, Murphy K, Stanton C, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015;26:26050.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Tsuji H, Takahashi T, et al. Gut dysbiosis following C-section instigates higher colonisation of toxigenic clostridium perfringens in infants. Benef Microbes. 2017;8(3):353–365.
   PubMed Web of Science ®Google Scholar
• Koleva PT, Kim JS, Scott JA, et al. Microbial programming of health and disease starts during fetal life. Birth Defects Res C Embryo Today. 2015;105:265–277.
   PubMedGoogle Scholar
• Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy. Front Microbiol. 2016;7:1031.
   PubMed Web of Science ®Google Scholar
• Perez-Muñoz ME, Arrieta MC, Ramer-Tait AE, et al. A critical assessment of the “sterile womb” and “in utero colonization” hypotheses: implications for research on the pioneer infant microbiome. Microbiome. 2017;5:48.
   PubMed Web of Science ®Google Scholar
• D’Argenio V. The prenatal microbiome: a new player for human health. Hig-Troughput. 2018;7(4):E38.
   PubMedGoogle Scholar
• Chu DM, Ma J, Prince AL, et al. Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery. Nat Med. 2017;23:314–326.
   PubMed Web of Science ®Google Scholar
• Dominguez-Bello MG, Costello EK, Contreras M, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107:11971–11975.
   PubMed Web of Science ®Google Scholar
• Bager P, Wohlfahrt J, Westergaard T. Caesarean delivery and risk of atopy and allergic disease: metaanalyses. Clin Exp Allergy. 2008;38:634–642.
   PubMed Web of Science ®Google Scholar
• Kuitunen M, Kukkonen K, Juntunen-Backman K, et al. Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort. J Allergy Clin Immunol. 2009;123:335–341.
   PubMed Web of Science ®Google Scholar
• Korpela K, Salonen A, Vepsäläinen O, et al. Probiotic supplementation restores normal microbiota composition and function in antibiotic-treated and in caesarean-born infants. Microbiome. 2018;6:182.
   PubMed Web of Science ®Google Scholar
• Poretsky R, Rodriguez-R LM, Luo C, et al. Strengths and limitations of 16S rRNA gene amplicon sequencing in revealing temporal microbial community dynamics. PLoS One. 2014;9:e93827.
   PubMed Web of Science ®Google Scholar
• Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017;474:1823–1836.
   PubMed Web of Science ®Google Scholar
• Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–180.
   PubMed Web of Science ®Google Scholar
• Koren O, Knights D, Gonzalez A, et al. A guide to enterotypes across the human body: meta-analysis of microbial community structures in human microbiome datasets. PLoS Comput Biol. 2013;9:e1002863.
   PubMed Web of Science ®Google Scholar
• Costea PI, Hildebrand F, Arumugam M, et al. Enterotypes in the landscape of gut microbial community composition. Nat Microbiol. 2018;3:8–16.
   PubMed Web of Science ®Google Scholar
• Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3:431–438.
   PubMed Web of Science ®Google Scholar
• ElRakaiby M, Dutilh BE, Rizkallah MR, et al. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. OMICS. 2014;18:402–414.
   PubMed Web of Science ®Google Scholar
• Kuntz TM, Gilbert JA. Introducing the Microbiome into Precision Medicine. Trends Pharmacol Sci. 2017;38:81–91.
   PubMed Web of Science ®Google Scholar
• Sharma A, Buschmann MM, Gilbert JA. Pharmacomicrobiomics: the holy grail to variability in drug response?. Clin Pharmacol Ther. 2019;106:317–328.
   PubMed Web of Science ®Google Scholar
• Haiser HJ, Gootenberg DB, Chatman K, et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium eggerthella lenta. Science. 2013;341:295–298.
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342:971–976.
   PubMed Web of Science ®Google Scholar
• Wikoff WR, Anfora AT, Liu J, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S A. 2009;106:3698–3703.
   PubMed Web of Science ®Google Scholar
• Sun J, Schnackenberg LK, Mendricka DL, et al. Evaluating effects of penicillin treatment on the metabolome of rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2013;932:134–143.
   PubMed Web of Science ®Google Scholar
• Swann JR, Tuohy KM, Lindfors P, et al. Variation in antibiotic-induced microbial recolonization impacts on the host metabolic phenotypes of rats. J Proteome Res. 2011;10:3590–3603.
   PubMed Web of Science ®Google Scholar
• Ufer M, Juif PE, Boof ML, et al. Metabolite profiling in early clinical drug development: current status and future prospects. Expert Opin Drug Metab Toxicol. 2017;13:803–806.
   PubMed Web of Science ®Google Scholar
• Doestzada M, Vila AV, Zhernakova A, et al. Pharmacomicrobiomics: a novel route towards personalized medicine? Protein Cell. 2018;9:432–445.
   PubMed Web of Science ®Google Scholar
• Robertson DG, Watkins P, Reily MD. Metabolomics in toxicology: preclinical and clinical applications. Toxicol Sci. 2011;120(S1):S146–S170.
   PubMedGoogle Scholar
• Beger RD, Sun J, Schnackenberg LK. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol. 2010;243:154–156.
   PubMed Web of Science ®Google Scholar
• Antonucci R, Pilloni MD, Atzori L, et al. Pharmaceutical research and metabolomics in the newborn. J Mat Fetal Neonat Med. 2012;25(S5):22–26.
   PubMedGoogle Scholar
• Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
   PubMed Web of Science ®Google Scholar
• Nimmesgern E, Benediktsson I, Norstedt I. Personalized medicine in Europe. Clin Transl Sci. 2017;10(2):61–63.
   PubMed Web of Science ®Google Scholar
• Caudle KE, Gammal RS, Karnes JH, et al. PRN OPINION PAPER: application of precision medicine across pharmacy specialty areas. J Am Coll Clin Pharm. 2019;2:288–302.
   Google Scholar
• Beger RD, Dunn W, Schmidt MA, et al. Metabolomics enables precision medicine: “a white paper, community perspective”. Metabolomics. 2016;12(10):149.
   PubMedGoogle Scholar
• Karlsson O, Hanrieder J. Imaging mass spectrometry in drug development and toxicology. Arch Toxicol. 2017;91:2283–2294.
   PubMed Web of Science ®Google Scholar
• Balluff B, McDonnell LA. Mass spectrometry imaging of metabolites. In: Giera M, editor. Clinical metabolomics. methods in molecular biology. Vol. 1730. New York, NY: Humana Press; 2018. p. 345–357.
   Google Scholar
• Mohs RC, Greig NH. Drug discovery and development: role of basic biological research. Alzheimers Dement (N Y). 2017;3(4):651–657.
   PubMedGoogle Scholar
• Ramamoorthy A, Karnes JH, Finkel R, et al. Evolution of next generation therapeutics: past, present, and future of precision medicines. Clin Transl Sci. 2019;12:560-563.
   Google Scholar
• Dugger SA, Platt A, Goldstein DB. Drug development in the era of precision medicine. Nat Rev Drug Discov. 2018;17(3):183–196.
   PubMed Web of Science ®Google Scholar
• Karnes JH, Miller MA, White KD, et al. Applications of immunopharmacogenomics: predicting, preventing, and understanding immune-mediated adverse drug reactions. Annu Rev Pharmacol Toxicol. 2019;59:463–486.
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214.
   PubMed Web of Science ®Google Scholar
• DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016;47:20–33.
   PubMed Web of Science ®Google Scholar
• Greene JA, Lea AS. Digital futures past - the long arc of big data in medicine. N Engl J Med. 2019;381(5):480–485.
   PubMed Web of Science ®Google Scholar
• Schüssler-Fiorenza Rose SM, Contrepois K, Moneghetti KJ, et al. A longitudinal big data approach for precision health. Nat Med. 2019;25(5):792–804.
   PubMed Web of Science ®Google Scholar
• Tolstikov V, Akmaev VR, Sarangarajan R, et al. Clinical metabolomics: a pivotal tool for companion diagnostic development and precision medicine. Expert Rev Mol Diagn. 2017;17(5):411–413.
   PubMed Web of Science ®Google Scholar